These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32198650)

  • 21. SWI/SNF Alterations in Squamous Bladder Cancers.
    Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
    J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.
    Rao Q; Williamson SR; Lopez-Beltran A; Montironi R; Huang W; Eble JN; Grignon DJ; Koch MO; Idrees MT; Emerson RE; Zhou XJ; Zhang S; Baldridge LA; Cheng L
    Mod Pathol; 2013 May; 26(5):725-32. PubMed ID: 23348900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
    Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
    Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation.
    Gopalan A; Sharp DS; Fine SW; Tickoo SK; Herr HW; Reuter VE; Olgac S
    Am J Surg Pathol; 2009 May; 33(5):659-68. PubMed ID: 19252435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
    Brunelli M; Tafuri A; Cima L; Cerruto MA; Milella M; Zivi A; Buti S; Bersanelli M; Fornarini G; Vellone VG; Rebuzzi SE; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Alongi F; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Antonelli A
    J Clin Pathol; 2022 Jan; 75(1):39-44. PubMed ID: 33144356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
    Oliva E; Amin MB; Jimenez R; Young RH
    Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion.
    Han L; Gallan A; Paner GP
    Am J Surg Pathol; 2019 Apr; 43(4):475-479. PubMed ID: 30475253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: a report of 7 cases and investigation using a limited immunohistochemical panel.
    Tamboli P; Mohsin SK; Hailemariam S; Amin MB
    Arch Pathol Lab Med; 2002 Sep; 126(9):1057-63. PubMed ID: 12204054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
    Amin A; Murati-Amador B; Lombardo KA; Jackson CL; Grada Z; Palsgrove DN; Matoso A
    Appl Immunohistochem Mol Morphol; 2020; 28(10):786-790. PubMed ID: 31876604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Villous Morphology in Urinary Bladder Biopsy: An Approach to Diagnosis.
    Mitra S; Ayyanar P; Kaur G
    Int J Surg Pathol; 2020 Feb; 28(1):4-12. PubMed ID: 31409167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Primary adenocarcinoma of the bladder. Apropos of 5 cases].
    Lacoste MJ; Lachard A; Coulange C; Gauvin C; Rampal M
    J Urol (Paris); 1985; 91(1):37-42. PubMed ID: 4045204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.